Health> Vol.5 No.4A, April 2013
Downloads: 460     Views: 1,207

Fatty acids composition of erythrocytes in arterial hypertension associated with dyslipidemia

ABSTRACT

Studied the fatty acid (FA) composition of erythrocyte membranes in patients with arterial hypertension associated with dyslipidemia. The fatty acid composition of erythrocyte membranes was studied by gaz chromatography. In all hypertensive patients are disturbed lipid FA composition of erythrocytes: increase in saturated fatty acids (15:0, 16:0), monoenic fatty acids (18:1n9, 18:1n7), polyunsaturated fatty acids (PUFA) family n6 (20:4n6), decrease in polyunsaturated fatty acids family n3:22:5n3, 22:6n3, the total value of n3 PUFA. Cells endogenous deficiency of n3 PUFA leads to the changes of the plasmatic membranes physicochemical properties, activation of eicosanoids synthesis with proinflammatory and vasoconstriction activity, the formation of the systemic inflammatory syndrome and conditions for the atherogenesis. Thus, structural and functional changes in erythrocyte membranes in hypertension developed as a part of the common systemic disorder of lipid metabolism.

KEYWORDS


Cite this paper

Novgorodtseva, T. , Karaman, Y. , Gvozdenko, T. , Antonyuk, M. and Knyshova, V. (2013) Fatty acids composition of erythrocytes in arterial hypertension associated with dyslipidemia. Health, 5, 73-77. doi: 10.4236/health.2013.54A010.

References

[1] Endakova, E.A., Novgorodtseva, T.P. and Svetashev, V.I. (2002) Modification of blood fatty acids composition in case of cardiovascular diseases. Vladivostok, 296.
[2] Titov, V.N. (2002) Atherosclerosis as a pathology polien fatty acids. Biological bases pathogenesis, diagnostics, preventive and treatment of atherosclerosis. M: Altus, 750.
[3] Titov, V.N. (1998) Violation of transport in cells of saturated fatty acids in the pathogenesis of essential hypertension. Vopr Med Khim., 44, 317-330.
[4] Novgorodtseva, T.P., Karaman, Y.K., Zhukova, N.V., Lobanova, E.G., Antonyuk, M.V. and Kantur, T.A. (2011) Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome. Lipids in Health and Disease, 10, 82. doi:10.1186/1476-511X-10-82
[5] Shalnova, S.A., Deev, A.D., Konstantinov, V.V. and Oganov, R.G. (2007) Hypertension and appraisal of the overall cardiovascular risk: Results of epidemiological monitoring of hypertension. Consillium Medicum, 11, 31- 35.
[6] Zvenigorodskaya, L.A., Homeric, S.G. and Egorova, E.G. (2008) Change the liver in insulin resistance. Hard Patient, 6, 71-74.
[7] Kuszakowski, M.S. (2002) Essential hypertension: Causes, mechanisms, clinical features, treatment. Pholiant, St. Petersburg, 416.
[8] Halperin, R.O., Sesso, H.D., Ma, J., Buring, J.E., Stampfer, M.J. and Gaziano, J.M. (2006) Dyslipidemia and the risk of incident hypertension in men. Hypertension, 47, 47-50.
[9] Psaty, B.M., Anderson, M., Kronmal, R.A., Tracy, R.P., Orchard, T., Fried, L.P., Lumley, T., Robbins, J., Burke, G., Newman, A.B. and Furberg, C.D. (2005) The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The cardiovascular health study. Archives of Internal Medicine, 165, 2420- 2427.
[10] Kovalenko, V.N., Mitchenko, E.I., Romanov, V.Y., Kulik, O., Logvinenko, A.A. and Gelmedova, M.F. (2008) Results of multicenter study to identify giperholeste rinemii-based analysis of regional centers of lipid. Ukrainian Journal of Cardiology, 8, 68-78.
[11] Sesso, H.D., Buring, J.E., Chown, M.J., Ridker, P.M. and Gaziano, J.M. (2005) A prospective study of plasma lipid levels and hypertension in women. Archives of Internal Medicine, 165, 2420-2427. doi:10.1001/archinte.165.20.2420
[12] O’Meara, J.G., Sharon, L.R., Armon, J.J., Brown, C.A., Boerwinkle, E. and Turner, S.T. (2004) Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Archives of Internal Medicine, 164, 1313-1318. doi:10.1001/archinte.164.12.1313
[13] Arnett, D.K., Jacobs, D.R., Luepker, R.V., Blackburn H., Armstrong C. and Claas S.A. (2005) Twenty-year trends in serum cholesterol, hypercholesterinemia and cholesterol medication use. The Minnesota heart survey, 1980- 1982 to 200-2002. Circulation, 112, 3884-3491. doi:10.1161/CIRCULATIONAHA.105.549857
[14] Goff, D.C., Bertoni, A.G., Kramer, H., Bonds, D., Blumenthal, R.S., Tsai, M.Y. and Psaty, B.M. (2006) Dyslipidemia prevalence, treatment, and control in the multi- ethnic study of atherosclerosis (MESA). Circulation, 113, 647-656. doi:10.1161/CIRCULATIONAHA.105.552737
[15] Anderson, K.M., Castelli, W.P. and Levy, D.B. (1987) Cholesterol and mortality: 30 years of follow-up from the Framingham study. Journal of the American Medical Association, 257, 2176-2180. doi:10.1001/jama.1987.03390160062027
[16] Liakishev, A.A. (2002) Correction of lipid disorders in patients with arterial hypertension. Russian Medical Journal, 10, 878-882.
[17] Kobalava, J.D. and Tolkachev, V.V. (2006) Hypercholesterolemia and arterial hypertension. Heart, 4, 172-176.
[18] Martsevich, S.Y. (2005) Treatment of lipid disorders in patients with coronary heart disease. Тreating Physician, 5, 42-45.
[19] Mitchenko, E.I. and Romanov, V.Y. (2007) The experience of the drug Cordon patients with arterial hypertension and dyslipidemia. Ukrainian Journal of Cardiology, 5, 73-77.
[20] Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R. and Simes, R. (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90056 participant in 14 randomised trials of statins. Lancet, 366, 1267-1278. doi:10.1016/S0140-6736(05)67394-1
[21] Graham, D.J., Staffa, J.A., Shatin, D., Andrade, S.E., Schech, S.D., La Grenade, L., Gurwitz, J.H., Chan, K.A., Goodman, M.J. and Platt, R. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid- lowering drugs. Journal of the American Medical Association, 292, 2585-2590. doi:10.1001/jama.292.21.2585
[22] Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R.E., Struijker Boudier, H.A. and Zanchetti, A. (2007) Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European society of hypertension (ESH) and European society of cardiology (ESC). Journal of Hypertension, 25, 1105-1187. doi:10.1097/HJH.0b013e3281fc975a
[23] Klimov, A.N. and Nikulicheva, N.G. (1999) Exchange of lipids and lipoproteins and its on-fracture: A guide for physicians. Peter Com, St Petersburg, 512
[24] Bligh, E.G. and Dyer, W.J. (1959) A rapid method of total lipid extraction and purification. Canadian Journal of Biochemistry and Physiology, 37, 911-917. doi:10.1139/o59-099
[25] Carreau, J.P. and Duback, J.P. (1978) Adaptation of a macroscale method to the microscale for fatty acid methyl transesterification of biological lipid extract. Journal of Chromatography, 151, 384-390. doi:10.1016/S0021-9673(00)88356-9
[26] Stransky, K., Jursik, T., Vitek, A. and Skorepa, J. (1992) An improved method of characterizing fatty acids by equivalent chain length values. Journal of High Resolution Chromatography, 15, 730-740. doi:10.1002/jhrc.1240151107
[27] Jamieson, G.R. (1975) GLC identification techniques for long-chain unsaturated fatty acids. Journal of Chromatographic Science, 13, 491-497.
[28] Medic, V.A. and Tokmachev, M.S. (2007) Mathematical statistics in medicine. Finances and Statistics, Moscow, 798.
[29] Potyomkin, V.V., Troitskaja, S.J. and Maksina, A.G. (2006) Metabolic indicators and struktura membranes erythrocytes at obesity and a metabolic syndrome at women. Russian Medical Journal, 1, 35-38.
[30] Novgorodtseva, T.P., Karaman, Y.K., Antoniuk, M.V. and Zhukova, N.V. (2009) The role of free and esterified fatty acids in pathogenesis of metabolic syndrome. Klinicheskaia Meditsina, 7, 33-37.

comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.